Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2006

View Archived Issues

Takeda presents highlights of previous nine months

Ferritin synthesis increased by small molecule binding to mRNA

Protection for gentamicin-evoked nephrotoxicity / News in Context

Pivotal phase II/III MS trial of MBP-8298 recommended to continue

Phase I trial investigates APD-668 for type 2 diabetes

ARYx completes Series E financing

Phase I SBIR grant supports preclinical work for ALS-886 for stroke

Oscient acquires expanded rights to ramoplanin

G2 Therapies and Novo Nordisk to collaborate on antiinflammatory therapies

Xyotax receives fast track designation for PS2 women with NSCLC

ReGen Therapeutics to acquire Sciencom

Open-label phase III extension study planned for Alzhemed in North America

FDA approves IND for first phase III bladder cancer trial for Bioniche's MCC

Selective apoptotic agent isolated from an actinomycete

MF-101 studied in phase II trial for treatment of menopausal symptoms

Generic name bremelanotide approved for PT-141

Avrina shows efficacy in eczema

Alvimopan reduces time to recover GI function following bowel resection surgery

NRP-290 bioavailability studied in phase I/II trial

Factor Xa inhibitor shows promise as an antimetastatic agent

COX-2 inhibitors reduce the risk of breast cancer

Recent patents disclose novel antiinfective agents

Novel agents for endocrine-related disorders reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...